Oral Delivery of Biologics Remains Unsolved — Most Require Injection

Biologic drugs (antibodies, peptides, proteins) represent ~40% of pharma revenue but almost all require injection because stomach acid and enzymes destroy them. Oral semaglutide (Ozempic) is a rare exception but requires a special absorption enhancer and achieves only ~1% bioavailability.

Biologics face three barriers to oral delivery: (1) enzymatic degradation by pepsin, trypsin, chymotrypsin in the GI tract; (2) the mucus layer and tight junctions of intestinal epithelium limiting absorption; (3) first-pass metabolism in the liver. Oral semaglutide uses SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) as a permeation enhancer, achieving ~1% oral bioavailability — meaning 99% of the drug is wasted. Nanoparticle encapsulation, mucoadhesive polymers, and intestinal patch technologies are in development but none have achieved commercialization for large biologics (>50 kDa).

Why It Matters

Global biologics market: ~$400B+. Patient compliance is significantly higher with oral vs. injectable drugs (80-90% vs. 50-60%). Eliminating cold-chain requirements for injection would transform distribution in developing countries.

Startup Approach

Develop a scalable oral delivery platform for biologics using ionic liquid formulations, mucus-penetrating nanoparticles, or intestinal injection devices. Focus on GLP-1 agonists first (massive market, proven demand for oral formulation) then expand to antibodies.

NIH Funding

NIBIB funds oral drug delivery research. NCATS supports translational delivery technologies. NIDDK funds oral insulin delivery studies.

Who's Working On It

Novo Nordisk (oral semaglutide), Rani Therapeutics (robotic pill), Entera Bio (oral peptide platform), Chiasma (oral octreotide, approved), Proxima Concepts